2 completed, 1 terminated, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Malignant Ovarian Clear Cell Tumor: new trials by email Literature Review of Malignant Ovarian Clear Cell Tumor trials Research Report on Malignant Ovarian Clear Cell Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer Epacadostat, Pembrolizumab - Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 14 | 2018-12-21 | 2024-07-26 |
| Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent Aldesleukin, HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis - Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor | Phase 1 | Withdrawn | Barbara Ann Karmanos Cancer Institute | 2015-06-01 | 2016-02-17 | |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 |
Ovarian Neoplasms (3) · Fallopian Tube Neoplasms (2) · Brenner Tumor (1)
Adnexal Diseases (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Gonadal Disorders (3) · Neoplasms (3) · Neoplasms by Site (3) · Ovarian Diseases (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Fallopian Tube Diseases (2)
130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Colony-Stimulating Factors (1) · Disulfides (1) · Immunoglobulin G (1) · Taxes (1) · aldesleukin (1) · epacadostat (1) · pembrolizumab (1) · sargramostim (1)
Barbara Ann Karmanos Cancer Institute (1) · Gynecologic Oncology Group (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1)
United States (3) · Puerto Rico (1)
Katherine Bell-McGuinn (1) · Lawrence Lum (1) · Lilian T Gien (1) · Matthew S. Block, M.D., Ph.D. (1)
U10CA180868 (2), P30CA022453 (1), U10CA027469 (1)